Gongwin Biopharm Holdings , Ltd. Overview

Gongwin Biopharm Holdings , Ltd. Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$19.05M

↓ 16.16% YoY

As of Jun 30, 2026

Annual R&D Expenses (TTM)

$125.93M

↑ 55.74% YoY

Trailing 12 months ending Jun 30, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin

Gongwin Biopharm Holdings , Ltd. (6617.TWO) FAQ

Stockcircle tracks research & development for Gongwin Biopharm Holdings , Ltd. (6617.TWO), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for Gongwin Biopharm Holdings , Ltd.'s historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main 6617.TWO overview so you can move from this figure to the surrounding analysis quickly.